Intra-lesional rF-B7.1 Versus rF-TRICOM vaccine in the treatment of metastatic cancer

Human Gene Therapy

Volumn 14, Issue 8, 2003, Pages 803-827

  Kaufman, Howard L ^a   Cheung, Kenneth ^a   Haskall, Ziv ^a   Horig, Heidi ^a   Hesdorffer, Charles ^a   Panicali, Dennis ^a   DeRaffele, Gail ^a   Spanknebel, Kathryn ^a  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; RECOMBINANT VACCINE; RF B7.1 VACCINE; RF TRICOM VACCINE; RF-B7.1 VACCINE; RF-TRICOM VACCINE;

ALLERGY; ANTIBODY TITER; ARTICLE; ASPIRATION BIOPSY; CHILL; CLINICAL PROTOCOL; FEVER; FOWLPOX VIRUS; HUMAN; HYPOTENSION; IMMUNE RESPONSE; IMMUNOASSAY; INJECTION PAIN; LYMPHADENOPATHY; METASTASIS; QUALITY OF LIFE; SKIN MANIFESTATION; VACCINIA VIRUS; ADULT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG FORMULATION; GENETICS; IMMUNOLOGY; INFORMED CONSENT; INTRALESIONAL DRUG ADMINISTRATION; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL;

FOWLPOX VIRUS; VACCINIA VIRUS;

ADULT; CANCER VACCINES; CLINICAL PROTOCOLS; CONSENT FORMS; DRUG COMPOUNDING; HUMANS; INJECTIONS, INTRALESIONAL; NEOPLASM METASTASIS; PATIENT SELECTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; VACCINES, SYNTHETIC;

EID: 0038359163     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303403765255183     Document Type: Article

References (33)

1. Horig H, and Kaufman HL. Current issues in cancer vaccine development. Clin. Immunol. 92, 211-223, 1999.
2. Bretscher P. The two-signal model of lymphocyte activation twenty-one years later. Immunol. Today 13, 74-76, 1992.
3. Watts TH, and DeBenedette MA. T cell co-stimulatory molecules other than CD28. Curr. Opin. Immunol. 11, 286-293, 1999.
4. Gimmi CD, et al. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc. Natl. Acad. Sci. USA 90, 6586-6590, 1993.
5. Harding FA, McArthur JG, Gross JA, Raulet DH, and Allison JP. CD28 mediated signalling co-stimulates murine T cells and prevents induction of anergy in T cell clones. Nature 356, 607-609, 1992.
6. + T cells by B7-transfected melanoma cells. Science 259, 368-370, 1993.
7. Baskar S, Clements VK, Glimcher LH, Nabavi N, and Ostrand-Rosenberg S. Rejection of MHC class-transfected tumor cells required induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules. J. Immunol. 156, 3821-3827, 1996.
8. Cavallo F, Martin-Fontecha A, Bellone M, Heltai M, Gatti E, Tornaghi P, Freschi M, Forni G, Dellabona P, and Casorati G. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur. J. Immunol. 25, 1154-1162, 1995.
9. Guinan EC, Gribben JG, Boussiotis VA, Freeman GJ, and Nadler LM. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 84, 3261-3282, 1994.
10. Wu T-C, Huang AYC, Jaffee EM, Levitsky HI, and Pardoll DM. A reassessment of the role of B7-1 expression in tumor rejection. J. Exp. Med. 182, 1415-1421, 1995.
11. Wingren AG, Parra E, Varga M, Kalland T, Sjogren H-O, Hedlund G, and Dohlsten M. T cell activation pathways; B7, LFA-3, and ICAM-1 shape unique T cell profiles. Critical Rev. Immunol. 15, 235-253, 1995.
12. + T cell activation but both are required for optimum response. J. Immunol. 155, 45-57, 1995.
13. Krummel M, and Allison JP. CD28 and CTLA-4 have opposing effects of the response of T cells to stimulation. J. Exp. Med. 182, 459-465, 1995.
14. Ostrand-Rosenberg S, Baskar S, Patterson N, and Clements VK. Expression of MHC class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells. Tissue Antigens 47, 414-421, 1996.
15. Schultze J, Nadler LM, and Gribben JG. B7-mediated costimulation and the immune response. Blood Rev. 10, 111-127, 1996.
16. Bluestone JA. Is CTLA-4 a master switch for peripheral T cell tolerance? J. Immunol. 158, 1989-1993, 1997.
17. Leach DR, Krummel MF, and Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734-1736, 1996.
18. + T cell- and IL-2-dependent mechanism. Immunity 11, 483-493, 1999.
19. Hodge JW, Mclaughlin JP, Abrams S, Shupert WL, Schlom J, and Kantor JA. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity. Cancer Res. 55, 3598-3603, 1995.
20. Hodge JW, Abrams S, Schlom J, and Kantor JA. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res. 54, 5552-5555, 1994.
21. Kaufman HL, Conkright W, Divito J Jr, Horig H, Kaleya R, Lee D, Mani S, Panicali D, Rajdev L, Ravikumar TS, Wise-Campbell S, and Suhrland M. A phase I trial of intra-lesional rV-B7.1 vaccine in the treatment of malignant melanoma. Hum. Gene Ther. 11, 1065-1082, 2000.
22. Kaufman HL. Personal communication, 2000.
23. Horig H, Lee DS, Conkright W, Divito J, Hasson H, LaMare M, Rivera A, Park D, Tine J, Guito K, Tsang, K-Y, Schlom J, and Kaufman HL. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol. Immunother. 49, 504-514, 2000.
24. von Mehren M, Arlen P, Tsang KY, Rogatko A, Meropol N, Cooper HS, Davey M, McLaughlin S, Schlom J, and Weiner LM. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin. Cancer Res. 6, 2219-2228, 2000.
25. Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, and Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 59, 5800-5807, 1999.
26. Hodge JW, Rad AN, Grosenbach DW, Sabzevari H, Yafal AG, Gritz L, and Schlom J. Enhanced activation of T-cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules. J. Natl. Cancer Inst. 92, 1228-1239, 2000.
27. Somogyi P, Frazier J, and Skinner MA. Fowlpox virus host range restriction: Gene expression, DNA replication, and morphogenesis in nonpermissive mammalian cells. Virology 197, 439-444, 1993.
28. Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobeigh M, and Shiomoto G. Reliability and validity of the functional assessment of cancer therapy - breast quality-of-life instrument. J. Clin. Oncol. 15, 974-986, 1997.
29. Fairclough DL, and Cella DF. Functional assessment of cancer therapy (FACT-G): Non-response to individual questions. Qual. Life Res. 5, 321-329, 1996.
30. Kammula US, Marincola FM, and Rosenberg SA. Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. J. Natl. Cancer Inst. 92, 1336-1344, 2000.
31. Heid CA, Stevens J, Livak KJ, and Williams PM. Real time quantitative PCR. Genome Res. 6, 986-994, 1994.
32. Kruse N, Pette M, Toyka K, and Rieckmann P. Quantification of cytokine mRNA expression by RT PCR in samples of previously frozen blood. J. Immunol. Methods 210, 195, 1997.
33. Panelli MC, Riker A, Kammula U, Wang E, Lee KH, Rosenberg SA, and Marincola FM. Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases. J. Immunol. 164, 495-504, 2000.